Animal models of chronic kidney disease - the missing piece of the puzzle for the development of new therapeutic options
Abstract
Chronic kidney disease (CKD) is considered one of the most important public health problems today. CKD is characterized by changes in kidney structure and impaired kidney function (reduced estimated glomerular filtration rate). Data show that more than 13% of the population suffers from CKD and that it will be the fifth leading cause of death by 2040. To date, numerous animal models for CKD have been developed. They are used to unravel the pathophysiological mechanisms of CKD development and represent a very important platform for the development of new therapeutic strategies. All animal models for CKD can be systematized in different ways, such as surgical/non-surgical models, subdivisions based on pathological changes in kidney structure or as subdivisions based on the pathophysiological mechanisms leading to the development of CKD. In surgical models, part of the kidney tissue is usually removed, while in non-surgical models, certain substances with nephrotoxic effects are used. The choice of model depends on the experimental design and the aim of the specific study. This paper provides an overview of all currently known animal models for CKD.
References
Levey A, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020;97(6):1117–29.
Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, WM McClellan, et al. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3(2):A57.
Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;3:S1–S150.
Liu P, Quinn RR, Lam NN, Elliott MJ, Xu Y, James MT, et al. Accounting for Age in the Definition of Chronic Kidney Disease. JAMA Intern Med. 2021;181(10):1359–66.
Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G. Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. J Clin Hypertens (Greenwich). 2021;23(4):831–4.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.
Ulasi I, Awobusuyi O, Nayak S, Ramachandran R, Musso CG, Depine SA, et al. Chronic Kidney Disease Burden in Low-Resource Settings: Regional Perspectives. Semin Nephrol. 2022;42(5):151336.
Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Adv Ther. 2022;39(1):33–43.
Lewandowski M, Krenn S, Kurnikowski A, Bretschneider P, Sattler M, Schwaiger E, et al. Chronic kidney disease is more prevalent among women but more men than women are under nephrological care : Analysis from six outpatient clinics in Austria 2019. Wien Klin Wochenschr. 2023;135(3–4):89–96.
Adair KE, Bowden RG. Ameliorating Chronic Kidney Disease Using a Whole Food Plant-Based Diet. Nutrients. 2020;12(4):1007.
Imenez Silva PH, Pepin M, Figurek A, Gutiérrez-Jiménez E, Bobot M, Iervolino A, et al. Animal models to study cognitive impairment of chronic kidney disease. Am J Physiol Renal Physiol. 2024;326(6):F894-F916.
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398:786–802.
Drew DA, Weiner DE, Sarnak MJ. Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention. Am J Kidney Dis. 2019;74(6):782–90.
Liang J, Liu Y. Animal Models of Kidney Disease: Challenges and Perspectives. Kidney360. 2023;4(10):1479–93.
Hosszu A, Kaucsar T, Seeliger E, Fekete A. Animal Models of Renal Pathophysiology and Disease. Methods Mol Biol. 2021;2216:27–44.
Eddy AA, López-Guisa JM, Okamura DM, Yamaguchi I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol. 2012;27(8):1233–47.
Outtandy P, Russell C, Kleta R, Bockenhauer D. Zebrafish as a model for kidney function and disease. Pediatr Nephrol. 2019;34(5):751–62.
Yang HC, Zuo Y, Fogo AB. Models of chronic kidney disease. Drug Discov Today Dis Models. 2010;7(1–2):13–9.
Deepthi R, Ganta S. A Review on Animal Models of Chronic Kidney Disease- An Update. Biomed Pharmacol J. 2023;16(3). doi: 10.13005/bpj/2711.
Fu Y, Tang C, Cai J, Chen G, Zhang D, Dong Z. Rodent models of AKI-CKD transition. Am J Physiol Renal Physiol. 2018;315(4):F1098-F1106.
Liu CZ, Chow KM, Chang TMS. Evaluation of two protocols of uremic rat model: partial nephrectomy and infarction. Ren Fail. 2003;25(6):935–43.
Adam RJ, Williams AC, Kriegel AJ. Comparison of the surgical resection and infarct 5/6 nephrectomy rat models of chronic kidney disease. Am J Physiol Renal Physiol. 2022;322(6):F639-54.
Hamzaoui M, Djerada Z, Brunel V, Mulder P, Richard V, Bellien J, et al. 5/6 nephrectomy induces different renal, cardiac and vascular consequences in 129/Sv and C57BL/6JRj mice. Sci Rep. 2020;10(1):1524.
Tan RZ, Zhong X, Li JC, Zhang YW, Yan Y, Liao Y, et al. An optimized 5/6 nephrectomy mouse model based on unilateral kidney ligation and its application in renal fibrosis research. Ren Fail. 2019;41(1):555–66.
O'Sullivan J, Finnie SL, Teenan O, Cairns C, Boyd A, Bailey MA, et al. Refining the Mouse Subtotal Nephrectomy in Male 129S2/SV Mice for Consistent Modeling of Progressive Kidney Disease With Renal Inflammation and Cardiac Dysfunction. Front Physiol. 2019;10:1365.
Bobot M, Thomas L, Moyon A, Fernandez S, McKay N, Balasse L, et al. Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction. J Am Soc Nephrol. 2020;31(7):1509–21.
Kim K, Anderson EM, Thome T, Lu G, Salyers ZR, Cort TA, et al. Skeletal myopathy in CKD: a comparison of adenine–induced nephropathy and 5/6 nephrectomy models in mice. Am J Physiol Renal Physiol. 2021;321(1):F106-19.
Zheng J, Lan P, Meng X, Kang MC, Huang X, Yan X. Na+/K+-ATPase DR region antibody ameliorated cardiac hypertrophy and fibrosis in rats with 5/6 nephrectomy. Exp Biol Med (Maywood). 2022;247(19):1785–94.
Hayashi K, Shimokawa T, Yamagata M, Yoneda K. Inhibition of α2-adrenoceptor is renoprotective in 5/6 nephrectomy-induced chronic kidney injury rats. J Pharmacol Sci. 2021;145(1):79–87.
Wang X, Chaudhry MA, Nie Y, Xie Z, Shapiro JI, Liu J. A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy. J Vis Exp. 2017;129:55825.
Wang Y, Zhang T, Cao X, Zou J, Ding X, Shen B, et al. Prostaglandin E2 induced cardiac hypertrophy through EP2 receptor-dependent activation of β-catenin in 5/6 nephrectomy rats. ESC Heart Fail. 2021;8(3):1979–89.
van Koppen A, Verhaar MC, Bongartz LG, Joles JA. 5/6th nephrectomy in combination with high salt diet and nitric oxide synthase inhibition to induce chronic kidney disease in the Lewis rat. J Vis Exp. 2013;77:e50398.
Karaduta O, Glazko G, Dvanajscak Z, Arthur J, Mackintosh S, Orr L, et al. Resistant starch slows the progression of CKD in the 5/6 nephrectomy mouse model. Physiol Rep. 2020;8(19):e14610.
Walkin L, Herrick SE, Summers A, Brenchley PE, Hoff CM, Korstanje R, et al. The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenesis Tissue Repair. 2013;6(1):18.
Bajwa NM, Lee JB, Halavi S, Hartman RE, Obenaus A. Repeated isoflurane in adult male mice leads to acute and persistent motor decrements with long-term modifications in corpus callosum microstructural integrity. J Neurosci Res. 2019;97:332–45.
Atkinson J, Boden T, Mocho JP, Johnson T. Refining the unilateral ureteral obstruction mouse model: No sham, no shame. Lab Anim. 2021;55(1):21–9.
Tan X, Li Y, Liu Y. Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol. 2007;103(3–5):491–6.
Benfield MR, McDonald RA, Bartosh S, Ho PL, Harmon W. Changing trends in pediatric transplantation: 2001 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 2003;7(4):321–35.
Aranda-Rivera AK, Cruz-Gregorio A, Aparicio-Trejo OE, Ortega-Lozano AJ, Pedraza-Chaverri J. Redox signaling pathways in unilateral ureteral obstruction (UUO)-induced renal fibrosis. Free Radic Biol Med. 2021;172:65–81.
Eddy AA, López-Guisa JM, Okamura DM, Yamaguchi I. Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol. 2012;27(8):1233–47.
Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol. 2001;281(5):F887–99.
Zager RA, Johnson AC, Becker K. Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and “end-stage” kidney disease. Am J Physiol Renal Physiol. 2011;301(6):F1334–45.
Hesketh EE, Czopek A, Clay M, Borthwick G, Ferenbach D, Kluth D, et al. Renal ischaemia reperfusion injury: a mouse model of injury and regeneration. J Vis Exp. 2014;88:51816.
Jia T, Olauson H, Lindberg K, Amin R, Edvardsson K, Lindholm B, et al. A novel model of adenine-induced tubulointers nephropathy in mice. BMC Nephrol. 2013;14:116.
Mulay SR, Eberhard JN, Pfann V, Marschner JA, Darisipudi MN, Daniel C, et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. Am J Physiol Renal Physiol. 2016;310(8):F785-95.
Yang Q, Su S, Luo N, Cao G. Adenine-induced animal model of chronic kidney disease: current applications and future perspectives. Ren Fail. 2024;46(1):2336128.
Wu B, Roseland JM, Haytowitz DB, Pehrsson PR, Ershow AG. Availability and quality of published data on the purine content of foods, alcoholic beverages, and dietary supplements. J Food Compos Anal. 2019;84:103281.
Yokozawa T, Zheng PD, Oura H, Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron. 1986;44(3):230–4.
Diwan V, Brown L, Gobe GC. Adenine-induced chronic kidney disease in rats. Nephrology (Carlton). 2018;23(1):5–11.
Al Za'abi M, Al Busaidi M, Yasin J, Schupp N, Nemmar A, Ali BH. Development of a new model for the induction of chronic kidney disease via intraperitoneal adenine administration, and the effect of treatment with gum acacia thereon. Am J Transl Res. 2015;7(1):28–38.
Saito H, Miyakoshi N, Kasukawa Y, Nozaka K, Tsuchie H, Sato C, et al. Analysis of bone in adenine-induced chronic kidney disease model rats. Osteoporos Sarcopenia. 2021;7(4):121–6.
Klinkhammer BM, Djudjaj S, Kunter U, Palsson R, Edvardsson VO, Wiech T, et al. Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy. J Am Soc Nephrol. 2020;31(4):799–816.
Bargagli M, Tio MC, Waikar SS, Ferraro PM. Dietary Oxalate Intake and Kidney Outcomes. Nutrients. 2020;12(9):2673.
Ermer T, Nazzal L, Tio MC, Waikar S, Aronson PS, Knauf F. Oxalate homeostasis. Nat Rev Nephrol. 2023;19(2):123–38.
Bao D, Wang Y, Zhao MH. Oxalate Nephropathy and the Mechanism of Oxalate-Induced Kidney Injury. Kidney Dis (Basel). 2023;9(6):459–68.
Bargagli M, Tio MC, Waikar SS, Ferraro PM. Dietary Oxalate Intake and Kidney Outcomes. Nutrients. 2020;12(9):2673.
Le Berre L, Godfrin Y, Günther E, Buzelin F, Perretto S, Smit H, et al. Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats. J Clin Invest. 2002;109(4):491–8.
Kim M, Piaia A, Shenoy N, Kagan D, Gapp B, Kueng B, et al. Progression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate Treatment. PLoS One. 2015;10(11):e0141231.
Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50.
Nagao S, Yamaguchi T. Review of the Use of Animal Models of Human Polycystic Kidney Disease for the Evaluation of Experimental Therapeutic Modalities. J Clin Med. 2023;12(2):668.
McGaha TL, Madaio MP. Lupus Nephritis: Animal Modeling of a Complex Disease Syndrome Pathology. Drug Discov Today Dis Models. 2014;11:13–8.
Martínez-Klimova E, Aparicio-Trejo OE, Tapia E, Pedraza-Chaverri J. Unilateral Ureteral Obstruction as a Model to Investigate Fibrosis-Attenuating Treatments. Biomolecules. 2019;9(4):141.
Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol. 1975;79(1):95–106.
Takeda N, Kume S, Tanaka Y, Morita Y, Chin-Kanasaki M, Araki H, et al. Altered unfolded protein response is implicated in the age-related exacerbation of proteinuria-induced proximal tubular cell damage. Am J Pathol. 2013;183(3):774–85.
Goldstein RS, Tarloff JB, Hook JB. Age-related nephropathy in laboratory rats. Faseb J. 1988;2(7):2241–51.
Schmitt R, Jacobi C, Susnik N, Broecker V, Haller H, Melk A. Ageing mouse kidney--not always the SAME old story. Nephrol Dial Transplant. 2009;24(10):3002–5.
Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003;23(5):486–99.
Ahmad A, Shi J, Ansari S, Merscher S, Pollack A, Zeidan Y, et al. Radiation nephropathy: Mechanisms of injury and recovery in a murine model. Radiother Oncol. 2023;187:109813.
Bryant C, Cianciolo R, Govindarajan R, Agrawal S. Adriamycin-Induced Nephropathy is Robust in N and Modest in J Substrain of C57BL/6. Front Cell Dev Biol. 2022;10:924751.
Naqvi R. Glomerulonephritis Contributing to Chronic Kidney Disease. Urol Nephrol Open Access. 2017;5(4):00179.
Reynolds J, Mavromatidis K, Cashman SJ, Evans DJ, Pusey CD. Experimental autoimmune glomerulonephritis (EAG) induced by homologous and heterologous glomerular basement membrane in two substrains of Wistar-Kyoto rat. Nephrol Dial Transplant. 1998;13(1):44–52.
Borza DB, Hudson BG. Of mice and men: murine models of anti-GBM antibody nephritis. Kidney Int. 2002;61(5):1905–6.
Foster MH. Optimizing the translational value of animal models of glomerulonephritis: insights from recent murine prototypes. Am J Physiol Renal Physiol. 2016;311(3):F487-95.
Ishizaki M, Masuda Y, Fukuda Y, Sugisaki Y, Yamanaka N, Masugi Y. Experimental mesangioproliferative glomerulonephritis in rats induced by intravenous administration of anti-thymocyte serum. Acta Pathol Jpn. 1986;36(8):1191–203.
Kaneko Y, Shiozawa S, Hora K, Nakazawa K. Glomerulosclerosis develops in Thy-1 nephritis under persistent accumulation of macrophages. Pathol Int. 2003;53(8):507–17.
Morita H, Isobe K, Cai Z, Miyazaki T, Matsumoto Y, Shinzato T, et al. Thy-1 antigen mediates apoptosis of rat glomerular cells in vitro and in vivo. Nephron. 1996;73(2):293–8.
Berchtold L, Friedli I, Vallée JP, Moll S, Martin PY, de Seigneux S. Diagnosis and assessment of renal fibrosis: the state of the art. Swiss Med Wkly. 2017;147:w14442.
Wu Q, Kuca K. Metabolic Pathway of Cyclosporine A and Its Correlation with Nephrotoxicity. Curr Drug Metab. 2019;20(2):84–90.
Lai Q, Luo Z, Wu C, Lai S, Wei H, Li T, et al. Attenuation of cyclosporine A induced nephrotoxicity by schisandrin B through suppression of oxidative stress, apoptosis and autophagy. Int Immunopharmacol. 2017;52:15–23.
Bing P, Maode L, Li F, Sheng H. Expression of renal transforming growth factor-beta and its receptors in a rat model of chronic cyclosporine-induced nephropathy. Transplant Proc. 2006;38(7):2176–9.
Young BA, Burdmann EA, Johnson RJ, Andoh T, Bennett WM, Couser WG, et al. Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int. 1995;48(2):431–8.
Yan LJ. Folic acid-induced animal model of kidney disease. Animal Model Exp Med. 2021;4(4):329–42.
Perales-Quintana MM, Saucedo AL, Lucio-Gutiérrez JR, Waksman N, Alarcon-Galvan G, Govea-Torres G, et al. Metabolomic and biochemical characterization of a new model of the transition of acute kidney injury to chronic kidney disease induced by folic acid. PeerJ. 2019;7:e7113.
Rattanasinganchan P, Sopitthummakhun K, Doi K, Hu X, Payne DM, Pisitkun T, et al. A folic acid-induced rat model of renal injury to identify biomarkers of tubulointerstitial fibrosis from urinary exosomes. Asian Biomed. 2016;10(5):491–502.
Hultström M. Development of structural kidney damage in spontaneously hypertensive rats. J Hypertens. 2012;30(6):1087–91.
Ni J, Yang F, Huang XR, Meng J, Chen J, Bader M, et al. Dual deficiency of angiotensin-converting enzyme-2 and Mas receptor enhances angiotensin II-induced hypertension and hypertensive nephropathy. J Cell Mol Med.2020;24(22):13093–103.
Fan X, Zhang W, Zheng R, Zhang Y, Lai X, Han J, et al. GSDMD Mediates Ang II-Induced Hypertensive Nephropathy by Regulating the GATA2/AQP4 Signaling Pathway. J Inflamm Res. 2024;17:8241–59.
Xu Z, Luo W, Chen L, Zhuang Z, Yang D, Qian J, et al. Ang II (Angiotensin II)-Induced FGFR1 (Fibroblast Growth Factor Receptor 1) Activation in Tubular Epithelial Cells Promotes Hypertensive Kidney Fibrosis and Injury. Hypertension. 2022;79(9):2028–41.
Maranduca MA, Clim A, Pinzariu AC, Statescu C, Sascau RA, Tanase DM, et al. Role of arterial hypertension and angiotensin II in chronic kidney disease (Review). Exp Ther Med. 2023;25(4):153.
Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl. 2002;82:S12-22.
Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73–81.
Pandey S, Dvorakova MC. Future Perspective of Diabetic Animal Models. Endocr Metab Immune Disord Drug Targets. 2020;20(1):25–38.
King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877–94.
Vaglio A, Gattorno M, McAdoo S, Obici LP, Ghiggeri GM. Editorial: The kidney in auto-immune and auto-inflammatory processes: Definitions, mechanisms, and biomarkers. Front Med (Lausanne). 2023;9:1129021.
Gorenjak M. Kidneys and Autoimmune Disease. EJIFCC. 2009;20(1):28–32.
Katayama R, Yamaguchi N, Yamashita T, Watanabe S, Satoh H, Yamagishi N, et al. Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample. J Pharmacol Toxicol Methods. 2010;61(1):59–64.
Gava AL, Freitas FP, Balarini CM, Vasquez EC, Meyrelles SS. Effects of 5/6 nephrectomy on renal function and blood pressure in mice. Int J Physiol Pathophysiol Pharmacol. 2012;4(3):167–73.
Selvarajah M, Weeratunga P, Sivayoganthan S, Rathnatunga N, Rajapakse S. Clinicopathological correlates of chronic kidney disease of unknown etiology in Sri Lanka. Indian J Nephrol. 2016;26(5):357–63.
Akan E, Cetinkaya B, Kipmen-Korgun D, Ozmen A, Koksoy S, Mendilcioğlu İ, et al. Effects of amnion derived mesenchymal stem cells on fibrosis in a 5/6 nephrectomy model in rats. Biotech Histochem. 2021;96(8):594–607.
Radloff J, Latic N, Pfeiffenberger U, Schüler C, Tangermann S, Kenner L, et al. A phosphate and calcium-enriched diet promotes progression of 5/6-nephrectomy-induced chronic kidney disease in C57BL/6 mice. Sci Rep. 2021;11(1):14868.
